Background
Familial Mediterranean Fever (FMF) is an autoinflammatory disease characterized by transient febrile episodes accompanied by abdominal and chest pain, arthralgia, myalgia, arthritis, and skin rash symptoms (1) . Mediterranean fever gene (MEFV) is localized on the short arm of chromosome 16 and encodes a 781-amino-acid protein known as pyrin (2) . FMF is also known as an autosomal recessive condition prevalent in Armenian, Turkish, and Arab populations. Renal involvement in FMF is usually attributed to secondary amyloidosis. Additionally, because of its auto-inflammatory nature, non-amyloid glomerular involvement has been described in some cases of FMF in literature, including mesangial proliferation glomerulonephritis (MePGN) with IgA or IgM deposit, focal or diffuse proliferative glomerulonephritis (GN), membranoproliferative GN and vasculitis with rapidly progressive glomerulonephritis (RPGN) renal course (3) (4) (5) (6) (7) . MePGN is a diffuse expansion of mesangial cells or matrix. It has different etiologies with highly variable clinical courses. Patients with MePGN and dominant IgA or IgM deposits are known as IgA or IgM nephropathy consequently (8) . In this cohort, the MEFV gene mutations were studied in a group of patients with idiopathic MePGN. Then clinical characteristics and the therapeutic response were compared between those with and without a mutation.
Objectives
We suppose that heterozygous mutation of Mediterranean fever (MEFV) gene could be the underlying cause in some cases of mesangial proliferative glomerulonephritis (MePGN) in FMF endemic area.
Materials and Methods

Patients selection
This prospective study was conducted in Kidney Research Center of Tabriz University of Medical Sciences from April 2013 to April 2015. The eligibility for inclusion criteria was all patients with light microscopy diagnosed MePGN, according to the WHO criteria (9) with negative immunoglobulin (Ig) deposition in immunofluorescence (IF) study (10) . Patients whose IF findings were consistent with IgA nephropathy, IgM nephropathy, C1q nephropathy, or presence of prominent C3 deposits, were excluded. Patients with systemic diseases such as active hepatitis, diabetes mellitus, malignancy, systemic lupus erythematosus (SLE), Henoch-Schonlein purpura, and mixed connective tissue disease were excluded from the study (11) . Complete remission (CR) was defined as proteinuria decrement below 500 mg/24 hours. Partial remission was considered as 50% decrease from baseline. No responders did change their protein excretion (10). We did not find enough literature to support our presumption that heterozygote FMF gene mutation without any clinical sign of FMF could be a possible cause for mesangial involvement; hence we did not start colchicine for these patients at the start. All patients received angiotensin receptor blockers and/or angiotensin converting enzyme inhibitors. Those with nephrotic range proteinuria at first received corticosteroid (1 mg/kg, for 8-12 weeks and then on tapering course). In non-responders, cyclosporine (2 mg/kg) was added to the therapeutic regiment. All patients were under regular nephrology clinic visit and proteinuria measurement for at least 6 months.
Gene study
Genomic DNA from peripheral blood leukocytes was extracted according to Miller et al protocol (12) . Five common mutations including M680I (G to C transversion), E148Q, M694V, M694I, and V726A were studied using PCR and PCR-restriction fragment length polymorphism (RFLP) approaches as described previously (12) (13) (14) (15) . For each test, proper positive and negative controls were used and the positive results were repeated in order to confirm the reproducibility. PCR and RFLP products were electrophoresed on an agarose gel (2%). Furthermore, patients with non-mutated allele(s) were examined for less common mutations including p.R408Q (c.1223G>A), p.E167D (c.501G>C), p.F479L (c.1437C>G), p.P369S (c.1105C>T), p.A744S (c.2230G>T) and p.R761H (c.2282G>A) based on the study of Medlej-Hashim et al (16) . Accordingly, suitable positive and negative controls were used and the positive results were repeated in order to confirm the reproducibility.
Ethical issues
The research followed the tenets of the Declaration of Helsinki. Our study protocol was approved by the ethics committee of Tabriz University of Medical Sciences (ethics code# IR.tbzmed.REC.1393.218). This study was conducted as the internal medicine residential thesis of Taraneh Majidi. The patients' medical records were used for data gathering and this process was secret.
Statistical analysis
Data analyzed was performed by analysis of variance (ANOVA) test and individual post-test comparisons were made for comparisons of interest and when the interaction was significant (P < 0.1). Comparison of quantitative variables between the two groups was tested using Mann-Whitney U test. Qualitative variables were tested by the chi-squared test. Statistical analysis was performed using the IBM SPSS software version 17.0. P value of <0.05 was statistically considered as significant.
Results
Demographic, clinical and laboratory characteristics of the studied patients (M/F: 22/17, mean age of 40.13±14.42, range; 16-57 years), have been shown in Table 1 . Heterozygote mutations of MEFV gene were more common among MePGN than controls (patients 11/39, 28.2%) versus (controls 46/156, 17.3%), but the difference was not significant (P = 0.12, Table 2 ). There was not a significant difference between mutation negative-MePGN and mutation positive -MePGN patients regard to their entry 24 hours urine protein excretion (Table 3) . However, after treatment and 6 months of follow-up complete response happened in the majority of mutation negative-MePGN compared to positives (P = 0.01, Table 4 ).
Discussion
We found that patients with MePGN and heterozygous mutations of MEFV genes had a lower therapeutic response in terms of proteinuria compared to MePGN patients without a mutation. Heterozygous mutation of E148Q was the most common mutation in our patients and also controls. In concordance with our results, heterozygous E148Q mutation has been reported among 12% of the Turkish population, 10% of Ashkenazi Jews, and up to 20% of our Iranian-Azari population (17) (18) (19) (20) . FMF is an autosomal recessive disorder, but the frequent discovery of clinical phenotype among patients with heterozygous mutations of MEFV gene suggested that the disease might be transferred as an autosomal dominant trait in some instances (21, 22) . Secondary amyloidosis is the main cause of renal involvement, however, various types of glomerulonephritis including MePGN have been reported in FMF patients (23) (24) (25) (26) . In a large report on 101 FMF patients, 12.3% had amyloidosis renal involvement, and 21.7% had non-amyloid renal lesions, including various types of glomerulonephritis (23) . The association between FMF and IgA nephropathy has been described previously (5) . The association between the clinically silent heterozygous mutation of MEFV gene and renal involvement is not too much discussed (24) . IgA nephropathy is the prototype of MePGN. Secondary MePGN is documented in a variety of disorders, such as systemic lupus erythematosus, Henoch-Schönlein purpura, rheumatoid arthritis, and vasculitic syndromes (27) (28) (29) . Therapeutic response to corticosteroid and colchicine has been reported in a few patients with MePGN who harbored heterozygous MEFV gene mutations (3, 4, 24, 26) . MEFV gene mutations upregulate the inflammatory cytokines including interleukin-1b and nuclear factor kappa B that may enhance the glomerular inflammation (6,26,30).
Conclusions
The results of our study indicated the possible underlying role of heterozygous MEFV gene mutation in the clinical course of some case of idiopathic MePGN, particularly in an endemic area. Therapeutic strategy in patients with MePGN and heterozygous MEFV gene mutation is still obscure. Addition of colchicine to their antiproteinuric therapy could be a useful suggestion (4) . Further studies with large populations are needed to explain the significance of the studied mutations on clinical progression of glomerulonephritis.
Study limitations
A small sample size due to the low incidence of the MePGN is our limitation in the present study.
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